| Abbreviation | Definition |
| H2AX | Phosphorylated histone H2A member X |
| ABCB1 | ATP Binding Cassette Subfamily B Member 1 |
| ALC1 | Amplified in liver cancer protein 1 |
| APLF | Aprataxin and PNKP like factor |
| APTX | Aprataxin |
| ATM | Ataxia telangiectasia mutated |
| ATR | Ataxia telangiectasia and Rad3 related |
| BARD1 | BRCA associated ring domain 1 |
| BER | Base excision repair |
| BID | Twice a day |
| BRCA1 | Breast cancer 1 |
| BRCA2 | Breast cancer 2 |
| CHK1 | Checkpoint kinase 1 |
| CSCs | Cancer stem cells |
| DDR | DNA damage response |
| DSB | double-strand break |
| DSD | Double-strand breaks |
| FDA | Food and Drug Administration |
| GIS | Genomic instability score |
| HER2 | Human epidermal growth factor receptor 2 |
| HGSOC | High grade serous ovarian cancer |
| HR | Homologous recombination |
| LOH | Loss of heterozygosity |
| LST | Large-scale State Transitions |
| MDR1 | Multidrug resistance 1 |
| MMR | Mismatch repair |
| MSI | Microsatellite instability |
| NAD | Nicotinamide adenine dinucleotide |
| NER | Nucleotide excision repair |
| NHEJ | HR and non-homologous end-joining |
| NuRD | Nucleosome remodeling deacetylase |
| PARG | Poly (ADP) ribose glycohydrolase |
| PARP | Poly (ADP–ribose) polymerase |
| PARP1 | Poly (ADP–ribose) polymerase 1 |
| PARP2 | Poly (ADP–ribose) polymerase 2 |
| PARP3 | Poly (ADP–ribose) polymerase 3 |
| PARPi | Poly (ADP–ribose) polymerase inhibitors |
| PFS | Progression free survival |
| PNKP | Polynucleotide kinase-phosphatase enzyme |
| RAD51 | RAD51 recombinase |
| RAD51C | RAD51 recombinase C |
| RAD51D | RAD51 recombinase D |
| RCA | Replication Comb Assay |
| SEER | Surveillance, Epidemiology, and End Results |
| SGO | Society for Gynecologic Oncology |
| SigMA | signature multivariate analysis |
| SSB | Single-strand breaks |
| TAI | Telomeric Allelic Imbalance |
| TMB | Tumor mutation burden |
| XRCC1 | X-ray repair cross-complementing 1 |